Skip to content
Peptide research

Retatrutide

Also known as LY3437943
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A synthetic triple-hormone peptide (GLP-1, GIP, glucagon) marketed for record-setting weight loss and metabolic improvement. Human evidence is strong: major weight loss, liver fat reduction, and blood sugar gains, though secondary benefits are less certain. GI side effects are common, long-term safety data are limited, and a theoretical thyroid tumor risk applies to the class. Not FDA-approved; most supply is unregulated research-grade material.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Record-setting weight loss (up to 24.2% at 48 weeks Phase 2; 28.7% at 68 weeks Phase 3)

    High

    Confirmed in a Phase 2 randomized trial; the higher Phase 3 figures are unpublished company data.

  • Dramatic liver fat reduction — 86% of MASLD patients achieved normal liver fat at 24 weeks

    High

    Phase 2a trial: 86% on the highest dose reached normal liver fat by week 24.

  • Substantial HbA1c reduction in type 2 diabetes (up to 2.02% at 24 weeks)

    High

    Phase 2 randomized trial showed a 2.02% HbA1c drop, later confirmed in a 2026 Phase 3 trial.

Evidence limits

Evidence Level
Strong Evidence

Phase 2 results published in NEJM, Lancet, and Nature Medicine. Phase 3 TRIUMPH program has 8+ trials enrolling 5,800+ participants. Five positive Phase 3 studies reported: TRIUMPH-1, -2, -3, -4 and TRANSCEND-T2D-1. Not yet FDA-approved.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Personal/family history of MTC

    Absolute

    Triple GLP-1/GIP/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.

  • History of pancreatitis

    High

    GLP-1 component carries pancreatitis risk.

  • Severe gastroparesis

    High

    GLP-1 component significantly slows gastric emptying.

General cautions

  • Pregnancy

    Absolute

    Investigational — no reproductive safety data.

Risk summary(7)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Gastrointestinal adverse events

    High
  • Dysesthesia (altered skin sensation)

    Moderate
  • Dose-dependent increase in heart rate

    Moderate
  • Pancreatitis (rare)

    Low
  • Gallbladder events (cholelithiasis)

    Moderate
  • Thyroid C-cell tumor risk (GLP-1 class warning)

    Theoretical
  • Limited long-term safety data

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.